MedTrace Logo

Open Label Prostate Cancer Study

NCT01162395 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2016-01-12

No results posted yet for this study

Summary

The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)

Conditions

Interventions

DRUG

AZD3514

Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.

Sponsors & Collaborators

Principal Investigators

  • Tony Elliott, MD · The Christie Hospital

  • Glen Clack, MD · AstraZeneca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
130 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-03-31
Completion
2015-10-31

Countries

  • United States
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01162395 on ClinicalTrials.gov